KZA Discussion 2022
- Thread starter zeeb0t
- Start date
Moosey
Emerged
Yes I am invested in KZA, I am hoping for big things from them this year, their cancer treatment for Glio Blastomer (Brain Cancer) and DIPG (childrens brain cancer) have shown some really good results, brain cancers are hard to treat, as many drugs today cannot pass the blood brain barrier Paxalisib KZA's drug is looking good, there have been no real developments in the treatments of brain cancer for over 30 years now.
Moosey
Emerged
This was posted by Rich and Poor over on the other site, Thanks R and P.
Alpelisib Discontinuation in Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer
Alpelisib is a phosphoinositide-3-kinase inhibitor approved for hormone-receptor-positive, PIK3CA-mutated metastatic breast cancer. However, length of drug exposure, maximum-tolerated dose, and therefore clinical response can vary significantly outside of the trial setting. This study evaluates our center's "real world" experience with alpelisib and focuses on duration of therapy and factors associated with cancer progression.
https://www.practiceupdate.com/c/13...ewsletter&rid=NDQ3MTgxOTYwMzc4S0&lid=20849617
https://www.practiceupdate.com/c/13...ewsletter&rid=NDQ3MTgxOTYwMzc4S0&lid=20849617
Piqray (alpelisib) - Novartis.
FDA approved - May 2019 for breast cancer
The PI3K inhibitor class is well-established, but paxalisib is unique in its ability to cross the blood-brain barrier.
Source :19-Jan-2022Kazia Corporate Presentation.
IMO, one door closes for alpelisib, with another door opening the possibility for paxalisib.
Alpelisib Discontinuation in Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer
Alpelisib is a phosphoinositide-3-kinase inhibitor approved for hormone-receptor-positive, PIK3CA-mutated metastatic breast cancer. However, length of drug exposure, maximum-tolerated dose, and therefore clinical response can vary significantly outside of the trial setting. This study evaluates our center's "real world" experience with alpelisib and focuses on duration of therapy and factors associated with cancer progression.
https://www.practiceupdate.com/c/13...ewsletter&rid=NDQ3MTgxOTYwMzc4S0&lid=20849617
https://www.practiceupdate.com/c/13...ewsletter&rid=NDQ3MTgxOTYwMzc4S0&lid=20849617
Piqray (alpelisib) - Novartis.
FDA approved - May 2019 for breast cancer
The PI3K inhibitor class is well-established, but paxalisib is unique in its ability to cross the blood-brain barrier.
Source :19-Jan-2022Kazia Corporate Presentation.
IMO, one door closes for alpelisib, with another door opening the possibility for paxalisib.
Similar threads
